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Abstract
Women of African descent are more likely to develop bacterial vaginosis (BV) and bear twice
the risk of preterm birth and the increased risk of other pregnancy complications. Sneathia amnii
is a pathogenic anaerobe found in the female urogenital tract that is associated with adverse
outcomes such as preterm birth, BV, and chorioamnionitis. S. amnii has been found at a greater
prevalence in the vaginal microbiota of women of African ancestry, which links it to a potential
role in the disparities observed in health outcomes for these women. S. amnii encodes the
cytopathogenic toxin A (CptA), an exotoxin that perforates fetal membranes and lyses red blood
cells. This study seeks to determine which domain of the cytotoxin (N or C-terminal) is
responsible for the cytotoxic and hemolytic activity. Our work has revealed that the C-terminal
domain is involved in binding to some host cell surface receptors and that the N-terminal domain
is the pore-forming domain. Our work also found evidence that the C-terminal binding domain
can competitively inhibit the cytolytic activity of full-length CptA, which suggests that the toxin
binds to a specific receptor and that binding is saturable. Advances in our understanding of CptA
and S. amnii pathogenicity will lead to a more educated approach to therapeutic intervention and
may reduce health disparities in gynecologic and obstetric complications associated with the
vaginal microbiome.
Keywords: Sneathia amnii, hemolysis, rounding, cytotoxin, bacterial vaginosis, preterm
birth
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Introduction
I.

Health Disparities in Research
Women of African are amongst people of minorities that are less likely to be included in

research studies. Although National Institutes of Health (NIH) Revitalization Act dictate the
inclusion of racial minorities in studies conducted in NIH-funded biomedical research, women of
African ancestry continue to still be underrepresented in research pertaining to diseases/
conditions that particularly affect their lives (Chinn et al 2021). Conversely, representation of
people of European ancestry continues to be prevalent in biomedical research (Bentley et al.
2020). This is troublesome as race and social factors influence the disease risk (Chen et al.
2014). Furthermore, women of African ancestry are at a higher disproportionate for health
disparities as issues pertaining to them are either overlooked, and women of the European
ancestry are set up as the standard for comparative analysis of disease risk. Therefore, based on
data presented for white women as well as interventions set in place for them are use across the
board to mitigate issues that affect subethnic groups.
Due to the lack of representation, women of African ancestry continue to face health
disparities as they exist in limited research, therefore limited data about conditions that plague
them and insufficient answers/ treatments to mitigate their problems proving detrimental to their
health and mortality overall (Chinn et al. 2021). Furthermore, the lack of representation for
women of African descent in research participation takes out the unique diverse perspective and
conditions that can be studied, limiting the scope of understanding in research, and diminishing
significant advancement to the field (Bentley et al. 2020). Thus, it is imperative to increase
inclusion of minorities especially women of African ancestry to further understand human
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biology, disease risks and to generate appropriate data that is truly representative of the
population (Bentley et al.2017).
II.

Healthy Vaginal Microbes and the Microbial Profiles of Women of African ancestry
A healthy vagina is colonized by Lactobacillus species that produce lactic acids to

maintain the vaginal pH of less than 4.5 (Fettweis et al. 2014; Jefferson 2012). The acidity of the
vaginal is essential for Lactobacillus species like L. crispatus to maintain a healthy microbial
community in the vagina by secreting lactic acid, hydrogen peroxide, and bacteriocins to protect
the vagina from colonization by other species (Jefferson 2012). The abundance of L. crispatus,
one of the stable Lactobacillus species, reduces the competition of other species that are instable
and pathogenic while L. iners, a less stable species, produce low lactic acid concentrations and
are dominant in higher vaginal pH (Verstraelen et al. 2009; Jefferson 2012; Vaneechoutte 2017).
Therefore, the reduction of various lactobacillus species reduces microbial protection against
idiopathic diseases such as bacterial vaginosis, pelvic inflammatory disease (PVD), and increases
the risk of experiencing preterm birth in women (Bayar et al. 2020; Jefferson 2012).
The microbial profiles of women of African American ancestry are more diverse because
they are low abundance of Lactobacillus bacteria and have high diversity profiles of anaerobic
pathogenic species (Fettweis et al. 2014). The abundance is relatively small in comparison to
women of European ancestry because the vaginal samples of women of African ancestry their
community is colonized with different dominant species of both Lactobacillus and anaerobic
species (Fettweis et al. 2014). The vaginal microbial profiles of healthy nonpregnant women of
African ancestry were populated with L. iners, Gardenella vaginalis, Parvimonas, Mycoplasma
hominis, and anaerobes like Sneathia, Porvetella species, BVAB1 and BVAB2, in comparison to
profiles of women of European ancestry which were predominantly populated with L. crispatus,
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L. iners, L. gasseri, Staphylococcus species and Gardenella vaginalis (Fettweis et al. 2014).
These bacterial species put African American women two times more at the risk of dealing with
negative pregnancy outcomes in comparison to women of European ancestry (Fettweis et al.
2014). Women of African ancestry compared to women of European descent are more likely to
exhibit microbial diversity, and they are more likely to contract bacterial vaginosis (BV), which
increases their risk for preterm birth (Fettweis et al. 2014).
III.

Bacterial vaginosis
The known cause of vaginal inflammation and the disturbance of the vaginal microbiome

is from bacterial vaginosis (BV) (Koumans et al. 2007). According to the National Health and
Nutrition Examination Survey conducted from 2001-2004, BV is prevalent at 29.2% in women
of all demographics within childbearing age (14-49), and 51.4% more prevalent in women of
African ancestry (Koumans et al. 2007). Similar studies that supported the prevalence of BV in
women of African ancestry reported that samples from women from ages 18 to 44 nonpregnant
women of which, 330 women were of European ancestry and 960 were women of African
ancestry, 22.8% of the African American women were diagnosed BV and only 6.5% in women
of European Ancestry (Fettweis et al. 2014). The study also concluded that risk factors for BV
include race/ethnicity, sexual partners, and in women with high frequencies of douching. Based
on sociodemographic factors, BV prevalence as high as the sexual partners increased when
looking at race (Koumans et al. 2007). BV is associated with many health risks including
susceptibility of HIV and other STIs as well as with the rates of PTB seen in women of African
ancestry. Pregnant Black women were more likely to experience adverse pregnancy outcomes
like give birth prematurely due to the prevalence of recorded BV (Koumans et al. 2007). Thus,
BV causes shifts in microbial community, which give rise to opportunistic microbes such as
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Sneathia amnii, which appears to be innocuous in the uterine cavity but becomes pathogenic
when the bacteria ascend the vaginal tract into the amniotic cavity.
IV.

Preterm birth
Preterm birth (PTB), defined as a live birth less than the 37 weeks gestation period, is a

universal health issue. Preterm birth is the major cause of the increase in neonatal mortality and
morbidity rates worldwide (Giurgescu et al. 2013; Walani 2020). According to the PTB
consensus from 2010, 184 countries, more than 25 million neonates are born preterm worldwide
(Walani 2020). Similarly, WHO reports that a global estimate of 13 million–17 million births are
preterm births with high rates, approximately 81.1% of these preterm births, occurring in South
of Asia and sub-Saharan Africa (Chawanpaiboon et al.2018). Of the millions of preterm births
worldwide, an estimated one million annual neonates deaths due to preterm birth complications
(Walani 2020).
PTB is categorized into different gestational ages. Extreme preterm is classified by birth
less than 20 weeks of gestation. Very Preterm Birth is noted by a gestation period more than 28
weeks but less than 32 weeks, and moderate-to-late preterm are births occurring between 32
weeks and 37 weeks (Jefferson 2012). Based on evidence from 67 countries, an estimate of
84.7% of PTB are grouped as moderate-to-late preterm births, and 11.3% are considered very
preterm births. Only 4.1% PTB occur within less than 28 weeks gestation period globally
(Chawanpaiboon et al. 2018). Of the estimate 15 million global score of annual preterm births,
an estimate of 750,000 babies is considered extreme preterm deliveries (Walani 2020). Preterm
birth neonates born less than 32 weeks and weigh less than 3.3lbs have lowest survival rates
(Goldenberg et al. 2000).
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V.

Sneathia Amnii
Sneathia amnii is a newly recategorized anaerobe pathogen once classified under the

Leptotrichia genus and was assigned the strain type named Sn35 (Collins et al. 2001; Harwich et
al. 2012). S. amnii was first isolated from mid vaginal samples of 736 women in outpatient
clinics across the state of Virginia (Harwich et al. 2012). In past studies, Sneathia species
including S. amnii was found in amniotic fluid collected from pregnancies associated with
preterm labor (Han et al. 2009). Research hypothesizes that intrauterine infections and
inflammations that are linked to preterm birth is through the ascension of pathogenic bacteria
like S. amnii from the cervix into the placenta and fetal membranes as noted in diseases like
chorioamnionitis where fluid from membrane rupture indicated the invasion of microbes
(Jefferson 2012). This means that preterm-associated bacteria species like cross from the
mother’s side to the fetal side and causes intra-amniotic infections and inflammation that lead to
preterm birth (Han et al. 2009).
According to recent studies, Sneathia amnii persists as a prevalent bacterial species in the
urogenital tract of women of African ancestry (Harwich et al. 2012; Fettweis et al. 2019).
Although Sneathia is prevalent in the human female vagina, it is understudied pathogen, which
can also infect men (Gentile et al. 2020;). Additionally, due to the lack of abundant research on
the bacteria and its role in the reproductive tract, there is hardly any published research about S.
amnii infections outside the reproductive tract (Duployez et al. 2020). The presence of Sneathia
in the uterine cavity is associated with negative pregnancy outcomes, perinatal and neonatal
complications as well as obstetrics complications (Harwich et al. 2012). The complications
include bacterial vaginosis, chorioamnionitis, amnionitis, preterm labor, stillbirth, and
spontaneous abortions in pregnant women and women of childbearing age (Harwich et al. 2012).
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It is also implicated in clinical conditions like PVD, infertility, salpingitis, and septic arthritis,
and it is involved in neonatal and perinatal complications such as meningitis (Gentile et al. 2020)
bacteremia. In men, it can lead to nongonococcal urethritis in men (Gentile et al. 2020).
Sneathia amnii is a gram-negative anaerobe with long-bacilli shaped morphology and
rounded ends (Harwich et al. 2012). Sneathia amnii requires specific medium human blood for
optimal growth and yields small flat colonies on blood agar in an anaerobic chamber (Gentile et
al 2020; Duployez et al. 2020). Moreover, based on the study conducted as part of the Vaginal
Human Microbiome Project at VCU. Sneathia species was determined as a predominant taxa in
the vaginal microbiome (Harwich et al. 2012). The study derived this conclusion based on the
abundance of Sneathia amnii identified by 16S rRNA analysis with more than 70% reads using a
0.1% abundance threshold and about 76.3% reads recognized as S. amnii presence in midvaginal samples, indicating its prevalence in the vaginal microbiome (Harwich et al. 2012).
Furthermore, this bacterium is the smallest sequenced fusobacteriacae and its genomic size is
approximately 1.34M base pairs with 1.2M bases making the DNA coding region (Harwich et al.
2012). Close analysis of the genome showed that the bacterium has a GC content of 28.3% and
852 genes associated with a putative function (Harwich et al. 2012).
S. amnii encodes an exotoxin, component A of the TPS called cytopathogenic toxin A
(CptA), which has cytotoxic and hemolytic capabilities. Using this exotoxin, Sneathia amnii
perforates membranes and lyses red blood cells (Gentile et al 2020). S. amnii genome contain
tandem genes for encoding two-partner secretion system that allows CptA to be exported into
epithelial cells to induce pore formation (Gentile et al. 2020). The bacteria’s genome contains
tandem genes that allow the secretion of the toxin via a Type Vb two-partner secretion (TPS)
system delivering the toxin, CptA, into epithelial cells to form pores in plasma membrane and
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induce osmolysis activity (Gentile et al. 2020). The Type Vb two-partner system is used by many
fastidious gram-negative bacteria to transport virulence factors like hemolysins, endotoxins and
other cytotoxins (Gentile et al. 2020). The two-partner secretion system has an effector coupled
with a beta barrel transporter that forms in the outer membrane to delivers CptA into epithelial
cells (Gentile et al. 2020). The CptA is the effector that the cognate transporter transports into the
outer membrane of cells (Gentile et al. 2020). Based on in-silico analysis of the toxin, it shares
similarities with well identified and studied region in Type Vb two-partner secretion system
found in Bordetella pertussis named filamentous hemagglutinin adhesin (Fha). Based on the
well-studied research about Fha, it is depended on its transporter, FhaC, to enter the outer
membrane to form beta-barrel forming pores (Mazar and Cotter 2007). Additionally, the
homology between CptA and Fha is 46% with only 261 aligned residues to CptA residues
(Gentile et al. 2020).
VI.

The exotoxin CptA
The toxin comprises of 1,881 amino acids and has an approximate molecular weight of

201kDA. It is a large protein, and the isoelectric point is 9.4 (Gentile et al. 2020). As mentioned
previously, CptA is best modelled after Fha in Bordetella pertussis with only 29% identity and
46% similarity (Gentile et al. 2020). CptA toxin has two separable domains hypothesis to have
independent functions – the amino-terminal domain (N-term) and the carboxy-terminal domain
(C-term) (Fig. 1). The N-term of the CptA contain the CptA gene locus which encode the CptA
protein that is responsible for pore-formation in cells (Gentile et al. 2020). The full length CptA
is approximately 6300 nucleotides long (Fig. 1). The N-term domain is 3,978 nucleotides in
length from the 5’ end of the cptA gene, and the C-term domain is 2370 nucleotides in length
from the 3’ end of the cptA gene (Fig. 1). Based on analysis, the full-length CptA has a protein
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size of 235 kDa. The amino terminal domain permeabilizes cells and has a protein size of
163kDa. On the other hand, the C-term is involved in binding to host surface receptors on
epithelial cells and is made up of 6 consecutive tandem repeats of 80 amino acids. The C-term
has protein size of the C-term is 99 kDa. There is little known about CptA and how it works.
CptBSTOPRevXh,

(4024 .. 4048) CptARepeats4VCptANTermRev (4024 .. 4048)

lptANoSigBam (70 .. 99)
2000

4000

' - - - - - - - - - ->

6000

N-Termlnal domain

C-Terminal Domain

Figure 1: Schematic of representation of full length CptA.

Figure 1: Schematic of representation of full length CptA and N-term and C-term domains of
CptA. Shown is the amino-terminal domain and the carboxy-terminal domain with appropriate
nucleotide length. Adapted from Dr. Jefferson.

VII.

Research Objectives
Based on previous works, researchers have implicated S. amnii in gynecologic and

obstetric complications associated with the vaginal microbiome. Furthermore, the exotoxin,
CptA, encoded by S. amnii is known to perforate membrane cells and lyse red blood cells. There
is little known about CptA and how it works. Therefore, advances in our understanding of CptA
and S. amnii pathogenicity will lead to a more educated approach to therapeutic intervention and
may reduce health disparities in women of African ancestry. Thus, the goal of this research is to
discover CptA and its role in host-pathogen interactions by establishing and investigating the
following objectives in this study:
1. Express the Full length CptA and the CptA domain peptides in E. coli cells and
purifying them. Our work revealed that the peptides could be successfully
expressed and purified.
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2. Determine which domain of CptA is responsible for the cytotoxic and hemolytic
activity. Our work has revealed that the C-terminal domain is involved in binding
to the host cell surface and that the N-terminal domain is the pore-forming
domain.
3. Identify the role of C-terminal binding domain in host-pathogen interactions. Our
work found evidence that the C-terminal binding domain can competitively
inhibit the cytolytic activity of full-length CptA, which suggests that the toxin
binds to a specific receptor and that binding is saturable.
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Materials and Methods
Culture conditions. The bacterial strain and plasmids used in this study are listed in Table 1.
Bacterial strain used in this study was BL21(DE3) pLysS + pRIL E. coli cells. The E. coli strain
was grown aerobically at 37C on Luria-Bertani (LB) broth medium and agar plates containing
100ug/ml ampicillin overnight. E. coli grown in liquid cultures were incubated aerobically in LB
broth at 37C in an incubator shaker (Incubator Shaker Model G25 New Brunswick Scientific
Co, Inc, Edison NJ) with heater for optimal oxygen supply to E. coli cells.
Table 1: Plasmid and bacterial strains.
Plasmid

Description

Source

pET32a

E. coli expression vector with T7 promoter, beta-lactamase gene
for ampicillin resistance, and N-terminal Trx/S-Tag/6X-His tag

Novagen

pET32NTerm

pET32 containing nucleotides 1-3,978 from the 5’ end of the cptA
gene.

Jefferson
Lab

pET32CTerm

pET32 containing nucleotides 3,979-6,349 from the 3’ end of the
cptA gene.

Jefferson
Lab

E. coli strain

Description

Source

BL21(DE3)
pLysS + pRIL
E. coli cells

Chemically competent cells derived from E. coli BL21 strain.
The BL21 strain is protease deficient. DE3 phage provides T7
to drive gene expression. pLysS plasmid suppresses basal
expression of T7 RNA polymerase until induction by IPTG.
pRIPL plasmid contains extra copies of genes that encode
tRNAs that are rare in E.coli but common in S. amnii.

Stratagene
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Agarose gel. 1% agarose-LE gel in 1X TAE. Ethidium bromide was added to the solution before
pouring. 6X loading dye was added to DNA samples. The gel was run at 100 volts in 1X TAE
buffer for 35 minutes. After separation, the DNA fragments were visualized under UV light.
DNA size was determined by comparing the DNA sample bands against λ/HindIII fragments.
Protein expression. The pET32a vector was used to express fragments of CptA proteins.
Proteins were expressed from the pET32a plasmids through the T7 promoter (Fig. 2). An
expression strain containing the pRIPL plasmid was used because certain codons, including
argU (AGA, AGG), ileY (AUA), proL (CCC), leuW (CUA) are rarely used in E. coli but much
more commonly found in the cptA gene from Sneathia amnii. The cells were inoculated in LB
medium with chloramphenicol and ampicillin overnight and placed in a 37°C shaker (Brunswick
Scientific Co.; Edison NJ). The cells were subcultured in 500 ml LB broth to mid-log phase at
37°C before pET32a vector with CptA fragment was added and incubated in the shaker
(Brunswick Scientific Co.; Edison NJ) for 2 hours.
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T7 promoter

►

lac operator

~

Xba I

TAA TACGACTC AC TA TAGGGGAA TTGT GAGCGGAT AACAA TTCCCCT CTAGAAA T AA TT TTGT TT AAC TTT AAGAAGGAGA

Trx•Tag

Hie•Tag

Msc I

TAT ACAT ATGAGC .. . 315bp .. . CTGGCCGGTTC TGGTTCTGGCCA T ATGCACCATCA TCATCATCA TTC TTCTGGTC TGGTGCCACGCGGTTC T
He t Ser
105cc .. . Leu AI oG l ySe rG l ySerG I yHi sHe t H I sH I sH I sH I sH I sH i sSerSerG I yleuVo I ProArgG I y Se r

S•Tag

~

S•Tag

~;Ji # 6 ~3

thrombin I

GGT ATGAAAGAAACCGC TGC TGC T AAA TTCGAACGCCAGCACA TGGACAGC CCAGATCT GGGT ACCGACGACGAC GACA AG
GI yMetL ysG I uThr A l oA I oA l olys PheG I uArgG I n H I sMe tAspSer Pro A spleuG I yThrAsp Asp Asp AspL y s
.
i:£T-32a(+)
Eag I
Ava I
I cntcrok1naec

Nool

EooRV&mt-tl EooR I Sacl

Sa/I

Hirx:1 111

Noll

Xhol

Hio·Tag

GCCATGGCTGA TA TCGGATCCGAA TTC GAGC TCCG TCGACAAGCTTGCGGC CGCACTCGAGCACCACCACC ACCACCAC TGAGATCCGGCT GCT AA
A I oMetA I oAs p I I eG I ySerG I uPheG I uleuArgArgG I nA I oCysG I yArgThrArgA I oProP roPr oProProleuArgSerG I yCysEnd

~I

T7 terminator

CAAAGCC CGAAAGGAAGC TGAGT TGGC TGCTGCCACCGC TGAGCAAT AACT AGCA T AACCCCTTGGGGCC TCT AAACGGGTCT TGAGGGGT TTTT TG
L ysPr oG I u Argl ysleuSer T rpleuleuProProleuSe rAsnAsnE nd

T7 terminator P'irnet" #69337-3

pET-32a-c(+) cloning/expression region
Figure 2: pET32a cloning plasmid expression vector.

Figure 2: pET32a cloning plasmid expression vector with T7 promoter, 6X His-Tag and the STag. Figure 2 cited from Novagen (LaVillie 1993).
Polyacrylamide gel electrophoresis. Protein gels were run using the NuPAGE SDS-PAGE
(Invitrogen). The running buffer for SDS-PAGE gel was prepared with 800 ml 1X MES running
buffer consisting of 20 ml of MES SDS running buffer and 760 ml of ddH2O. 10 ul NuPAGE 4X
LDS Sample Buffer and 4 ul reducing buffer agent was added and mixed into 30 ul of sample.
The samples were incubated in a heat block for 10 minutes, at 85°C and 20 ul of sample was
loaded into the wells of NuPAGE 4-12% Bis-Tris 1.0 mm Gel. The gel was run at 200 volts in
1X NuPAGE Running Buffer for 30 minutes. Protein band size was determined by comparing
the protein sample bands against BLUEstain protein ladder. After electrophoresis, the gel was
washed twice with ddH2O and placed on an orbital shaker to develop and for visualization.
Lysis of E. coli for the Purification of recombinant proteins. Protein was expressed in the
BL21(DE3) pLysS + pRIL strain of E. coli. The frozen induced BL21(DE3) pLysS + pRIL +
pET32a pellet was resuspended on ice with lysis buffer made using 250ml of 1X PBS and 100
mM NaCl (1.46 g) and one protease inhibitor tablet [cOmplete, EDTA-free protease inhibitor
cocktail tablet] (Roche Diagnostics GmbH, Germany). The resuspended pellet was lysed with a
French press 4 times. After lysis, the lysate was spun down in a centrifuge at 25000 RPM for 20

13
mins at 4°C. The supernatant was filtrated using a syringe capped with a pre-filter and a 0.45 um
pore filter.
Protein Purification by Metal Ion Chromatography. The filtered protein was purified by
nickel ion affinity chromatography. The purification column was prepared with 2.5 ml of
Probond™ Resin (nickel beads) (Invitrogen Life Technologies Carlsbad, CA), which was
washed with 11 ml of ddH2O and equalized with 10 ml of 100 mM NaCl and 10X PBS buffer.
The ProBond buffer was made with 25 ml of 10X PBS and 100 mM NaCl and detergent. The
elution buffer was made with 250 ul of Ultra-Pure distilled water and 2.5 ml of 1M imidazole
(IM). The filtered lysate was first added to nickel column and collected flow through for further
analysis for cytotoxicity. The lysate in the resin column was washed 4 times with probond
buffer, and the column was eluted with elution buffer. The column was eluted with 2 ml of
dilution of imidazole at 1 M, 500 mM, 250 mM and 125 mM. At each step of the protein
purification protocol, 50 ul aliquots of each step were saved in -80°C for further analysis. This
procedure was done in a cold room. The same procedure was done performed with C-term
fragment. SDS-PAGE Electrophoresis was performed with the saved aliquots to track the
protein. The samples were prepared for SDS-PAGE using 50 ul of samples, 20 ul loading buffer
and 7 ul reducing agent and heat in heat block for 10 mins. The 30 ul was loaded into each well
as well as the 5 ul of molecular ladder. The gel was run for 30 minutes at 200V.
HeLa Cell Binding Assay and SDS-PAGE gel. HeLa cell monolayers were cultured in T25
flasks. The media was removed, and the HeLa cells were washed with 5 ml of PBS. Purified,
recombinant N-term or C-term at a concentration of 5ug protein/mL in PBS or PBS alone, was
added to T25 flasks 7 and the samples were incubated in 5% CO2 incubator for 15 minutes. The
cells were scrapped into 1 ml of SLS NuPAGE loading buffer (Invitrogen), sonicated for 30
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seconds to break up DNA and put on heat block for 10 minutes at 85°C. Separate
microcentrifuge tube containing either N-term or C-term peptides was mixed with a reducing
buffer and put on a heat block with the rest of the samples. 20 ul of sample was loaded into each
well of NuPAGE 4-12% Bis-Tris 1.0 mm Gel. The organization of the well is listed below:
1. 5 ul MW size marker
2. 20 ul of cells alone with PBS
3. 20 ul of CptA/N-term alone
4. 20 ul of CptA/N-term + Hela cells
5. 20 ul of C-term alone
6. 20 ul of C-term + Hela cells
The SDS-PAGE gel was electrophoresed at 200V for 30 minutes.
Prepared the transfer buffer and protein transfer. Transfer buffer was made with 40 ml of
1X NuPAGE (Invitrogen) added with 610 ml of ddH2O and 150 ml of methanol. A 0.45 um
PVDF membrane (Invitrogen, Grand Island, NY) was pre-wetted in 100% methanol for 30
seconds to 1 minute. Transfer filter paper and sponges were soaked and saturated in the transfer
buffer as well as the PVDF membrane was rinsed with transfer buffer for a few minutes.
Following polyacrylamide gel electrophoresis, the gel was prepared for transfer by rinsing in
ddH2O and then placed against the PVDF membrane carefully to eliminate bubbles, which would
inhibit the transfer of proteins. The gel and PVDF membrane were surrounded by the transfer
filter paper and sponges to maintain buffer saturation and tight contact between the membrane
and gel, and the same 1X NuPAGE transfer buffer. The SDS-PAGE electrophoresis gel was run
for 1 hour at 35 volts.
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Western blot to detect 6X-His-tagged proteins. The blocking buffer contained 5% skim milk
diluted in 1 X PBS. The wash buffer was prepared using 1X PBS and 0.05% Tween 20 (PBS-T).
The PVDF membrane was soaked in the milk blocking buffer made of 5% skim milk diluted in
10X PBS for 1 hour, while rocking on an orbital shaker at room temperature. The milk blocking
buffer was removed and replaced with a 1:10,000 dilution of anti-6X HIS Tag primary antibody
in PBS-T. The PVDF membrane was agitated on the orbital shaker gently for 1 hour. After the
hour, the solution was poured out and the PVDF membrane washed three times for 5 minutes in
1X PBS-T. The PVDF membrane was probed with 1:10,000 goat anti-rabbit immunoglobulinhorseradish peroxidase conjugate (Invitrogen, Grand Island, NY) in 1X PBST for 1 hour at room
temperature and rocked on the orbital shaker. The PVDF membrane was rinsed at room
temperature with PBST three times for 5 minutes and once with ddH2O. In the dark room,
protein bands were developed using the saran wrap and ECL prime kit (GE Healthcare) to detect
protein and measure the protein size. The blot was incubated in the chemiluminescence
developing reagent for 1 minute, covered in saran wrap, exposed to X-ray film and developed in
an X-O-Mat. The bands visualized were compared to BLUEstain protein ladder (Gold-Bio).
Cell culture. HeLa cells were cultured in a 5% CO2 incubator at 37°C in minimum essential
media (EMEM) (Quality Biological, Gaithersburg, MD). HeLa cells were viewed under an
inverted microscope for more than 70% confluence. The old EMEM was aspirated off the HeLa
cells and discarded. The cells were washed in PBS and aspirated. The adherent cells were then
covered with trypsin and returned to the incubator at 37°C and 5% CO2 for 5 to 10 minutes for
the cells to dislodge from the surface of the flask. The EMEM cell media was added to the cells
and resuspended. The cells were split 1:10 split of cells into a new T25 flask with 1 ml of cell
and 9 ml of fresh EMEM cell media or 1:20 split with 4 ml of cells into 6 ml of fresh new
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EMEM. The remaining cells were split into 12 well plates with 0.5 ml per well. The cells were
incubated in a 5% CO2 incubator at 37°C, and the cells were passed every 4 days.
Hemolytic Assay. The purified peptides were incubated with human erythrocytes washed in
PBS for 2 hours at 37ºC. The liberated hemoglobin was measured by optical density at 405nm
via spectrophotometry (Biomate 3 Thermo Electron).
Cytotoxic assay with terminal domains of CptA. Cytotoxicity and cell permeabilization were
monitored using an inverted microscope (EVOS) (Life Technologies, Carlsbad, CA). Media was
aspirated from the wells, and the cells were washed with PBS. PBS was added to each well, and
30 ul of N and C term peptides were added to HeLa cells and incubated in a 5% CO2 incubator at
37°C for 2 hours. The cells were visualized, and images were taken with an inverted microscope
EVOS AMEX-100 microscope (Life Technologies, Carlsbad, CA) to examine membrane
permeability and cell morphology of HeLa cells. Trypan blue (Thermo Scientific, Waltham,
MA) at 1:3 dilution was added to each cell and let to set for 2-3 minutes. The trypan blue was
aspirated off the well and viewed under microscopy. The cells were analyzed using trypan blue
exclusion method. The cytotoxic assay was repeated with saved aliquots from the purification
steps.
Cytotoxic assay with terminal domains of CptA at different volumes. The cytotoxic assay
performed on HeLa cells was done to monitor cytotoxicity and cell permeabilization under an
inverted microscopy. The old media in the wells in the 24-well plate were aspirated, and the cells
were washed with PBS. 250 ul PBS was added to each well with the exception of 500 ul added to
the first column of well-plate. C-term was done with different volumes of C-term added to the
1st 2nd and 3rd row. 5 ul of C-term was added to the wells across the well plate in the first row.
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In the second row, C-term was added at 0.5 ul volumes to each well in the second row and 0 ul in
the 3rd row. The fourth row served as the negative control. 3 ul of CptA was added to each well
in the first column and serial dilution was carried out by pipetting 250 ul across the wells. The
HeLa cells were incubated in a 5% CO2 incubator at 37C for 2 hours. The cells were visualized
under an inverted microscope to examine membrane permeability and cell morphology of HeLa
cells. Trypan blue at 1:3 dilution was added to each cell and let to set for 2-3 minutes. The trypan
blue was aspirated off the well and viewed under microscopy. The cells were analyzed using
trypan blue exclusion method. The cytotoxic assay was repeated with different volumes of Cterm and N-term.
In silico analysis. FASTA format sequence retrieved from NCBI was used to model the
structure of toxin. The FASTA sequence of Sneathia amnii CptA document taken from Dr.
Jefferson and ran that into n-BLAST. Based on Gentile et al. 2020, the CptA toxin was served
for using command+F with keyword VC03_06090. The derived protein FASTA sequence for
CptA was run in Phyre 2.0 software at normal mode using the sequence.
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Results
The full-length CptA and the domains of CptA, N-term and C-term, were successfully
expressed and purified.
The two domains of CptA, the structured amino-terminal, and the globular carboxy-terminal
domain were cloned into pET32a expression vectors. The proteins were expressed in the
BL21(DE3) pLysS + pRIL strain of E. coli cells. In Figure 3, full length CptA was purified by
nickel ion column. Based on the SDS-PAGE analysis, the saved aliquots from the purification
steps of CptA had faint bands appear at ~240 kDa. The bands did not appear when photographed,
but when the gel was viewed physically, light band at ~240 kDa was seen in the 10 mM lane, but
it was not captured on camera. The breakdown of the peptides appeared across all the columns
with the different dilutions of imidazole. We expected a messy column for the lysate and less
smearing for 500 mM IM.
In Figure 4, SDS-PAGE analysis was performed after purification of the full-length CptA
and C terminal domain of CptA by nickel ion column. In Fig. 4, the proteins of the full length
CptA and C-term domain were eluted from the nickel beads with 10 mM, 100 mM, or 250 mM
imidazole. The proteins were seen for the C terminal domain at 98 kDa, and the full-length CptA
was viewed at 235 kDa. The C-term domain was 80 kDa plus the 17.9 kDa tag. Similar to Fig. 3,
the breakdown of the peptides was seen with the smearing of the bands. As expected, the
smearing indicative of protein breakdown was seen in the flow through lane. It is our assumption
that the breakdown of the peptides may be due to CptA protein being autocatalytic that is why
we see the other bands appear. This hypothesis needs to be further investigated. Furthermore,
due to the grand size of the domain terminal peptides, lack of separation of the peptides leads to
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the smearing. The purified terminal peptides were eluted with and the bands were prominent.
The peptides of C-term were seen at 98 kDa, and the full length CptA was viewed with bands at
235 kDa. In Figure 5, the purified domain peptides of C-term and N-term of CptA were
visualized on SDS-PAGE gel after the peptides were eluted from the nickel beads with 10mM,
100 mM, or 250 mM imidazole. The C-term domain was 80 kDa plus the 17.9 kDa tag and the
N-term domain was 145 kDa plus the 17.9 kDa tag. The bands appeared at 98 kDa for C-term
domain of CptA and 163 kDa at N-term domain of CptA.
Both the N-term and C-term bound to HeLa cells
To investigate how the terminal domains of CptA interacted with HeLa monolayers, we
added the purified domain peptides to HeLa cells and incubated for 15 mins. Then the cells were
washed in PBS to remove the nonadherent proteins leaving the adherent within the HeLa cells.
The cells were then sonicated to break up the cells and release the DNA and the samples for each
adherent domain protein in the HeLa cells were run on an SDS-PAGE gel. The proteins were
transferred to an PVDF membrane and was probed with both the primary antibody, anti-6X HIS
Tag, and the secondary antibody, goat anti-rabbit immunoglobulin-horseradish peroxidase
conjugate, and the bands were visualized by western blot. In Figure 6, the HeLa cells in the
second lane served as the negative control and showed that the antibodies used for probing did
not tag the proteins of the HeLa cells as indicative with no bands showing in the lane. Both the
N-term or C-term peptides alone were added and served as positive control to show where the
bands were supposed to appear. In Figure 6, in the N-term lane, we see multiple bands appearing
in the lane. However, this is the only clearly the only visible bands present only in the N-term
peptide alone lane with less lightly visible bands in the N-term bands added to HeLa cells and Cterm peptide alone and absolutely no bands present in the C-term peptides added to HeLa cells. It
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was our assumption that the malfunctioning of the western blot and the lack of inaccuracy of
corresponding bands to the appropriate molecular marker of protein size was due to many
possibilities including a lower concentration of the C-term peptide being added which although
appeared on the SDS-PAGE gel, did not transfer to the PVDF, and was lost and that the N-term
peptide concentration was twice as the concentration of the C-term peptide. Another possibility
we considered was mutations in E. coli cells at the 6X His tag mutated from Histidine to proline,
so the primary antibody was unable to probe the peptides. Thus, this was rectified in a second
Western blot done by Mr. Jacob Raskind of VCU using an antibody for the S-tag as shown in
Fig. 7. In Figure 7, the bands for the N-term peptide appeared appropriately around 240 kDa.
However, a second was present, it was our assumption that maybe due to the autocatalytic nature
of the toxin, it breaks down and the breakdown peptides were tagged.
Similar to the bands that appeared for the N-term peptides alone, the adherent N-term
peptides in HeLa cells also had similar bands in the same range when compared to the N-term
peptide alone bands. Furthermore, bands appeared for the C-terminal domain alone with
smearing also present with the bands. Again, this may be due to peptide break down. However,
the protein size of about 99 kDa was clearly visible in the lanes with the C-term peptides added
to the HeLa cells. The appearance of bands in both the N-term added to HeLa cells and C-term
added to HeLa cells lanes shows that both the N-term and the C-term peptides were adherent
proteins and bound to HeLa monolayers. Additionally, in the western blot, the N-term and Cterm were added to empty wells to test to adherence of the peptide to any surface. The lack of
bands confirmed our assumption that the CptA’s terminal domain peptides did not just adhere to
any surface. Both the C-term and N-term were adherent to epithelial monolayer cells.
CptA N-term is hemolytic
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We incubated the purified CptA peptide with human erythrocyte cells washed in PBS for
2 hours at 37ºC. The liberated hemoglobin was measured at optic density of 405 nm. In Fig. 8,
N-terminal domain is hemolytic as a high absorbance was indicative of hemolysis seen at
500mM dilution with imidazole. N-terminal domain is hemolytic.
CptA N-term is cytotoxic, and C-term is not cytotoxic
In Figure 9, The N-term of CptA was cytotoxic and the C-term of CptA was not
cytotoxic. In Figure 9A, N-term was capable of cell permeabilization and the N-term has an
affinity for HeLa cell plasma membrane. The N-term permeated epithelial cells as noted by
trypan exclusion. All the dead cells stained blue. In the HeLa cells in Figure 9B shows C-term
added to HeLa cells. In Figure 9B, C-term did not permeate cell membrane as noted with less
death. The C-term bound to some specific host cell receptors on HeLa monolayer cells. In the Cterm, some rounding of the HeLa cells is noticed but not so much, as majority of the cells
captured have their regular cell morphology that depict tear-shaped angular shaped with growth
pattern of patchy monolayer.
C-term inhibited full-length CptA, possible competitive binding mechanism to some host
surface receptor.
In Figure 10, C-term peptide to prevent full-length toxin-mediated cytotoxicity. When the
N-term alone was added to HeLa cells, cell permeabilization was evidenced by trypan blue (Fig.
10). This supports our hypothesis that N-term peptides have an affinity for plasma membranes.
We further discovered that when C-term was first added to the HeLa cells before the CptA, we
discovered that the C-term inhibited the cell permeabilization of the HeLa monolayers. There
were less cells stained with trypan blue. This lead and supports our hypothesis that C-term may
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be participating in competitive binding kinetics to host surface receptors on HeLa cells and that
binding is saturable.
In-silico analysis for protein structure of CptA
The results show homologous similarity of CptA structure to full-length FhaB in
Bordetella as shown in Figure 11. The results also showed that the CptA sequence aligned to
hemolysin in P. mirabilis. Based on in0silico analysis, 11% of the sequence (215 residues) was
modelled with 100.0% to a highest scoring template. The proteins structure was modeled after
template c3fy3A_ ranked #1, and it indicated the whole chain of the protein of modeled protein
was a toxin, and the PDB molecule was hemolysin with crystal structure of truncated hemolysin
a from p. mirabilis. The confidence level of the template c3fy3A_was 100, but the % identity
was 26. Furthermore, based on analysis via the Phyre2.0 software, 772 residues (41%) could be
modelled at >90% confidence using multiple-templates and 80% of CptA sequence was
disordered and cannot be meaningfully predicted (Fig. 11). Furthermore, 3% of the sequence was
alpha helix and 62% beta strands. A second hit was found with 100 confidence level for template
d1rwra_ with a 29% identity. The second template matching to CptA sequence aligned with 261
residues, and this template was indicative of a domain of the protein. The template d1rwra_
characterized as a single-stranded right-handed beta-helix (Fig. 11). Additionally, the
superfamily of the template d1rwra_ was Pectin lyase-like, and the family was Filamentous
hemagglutinin FhaB, which is a secretion domain.
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Figure 3: Purification of S. amnii full length CptA recombinant proteins

Figure 3: Purification of S. amnii full length CptA recombinant proteins. Purification of 6X-His
tagged recombinant CptA expressed in BL21(DE3) pLysS + pRIL strain of E. coli cells
containing pET32a using a nickel resin column. The samples loaded were compared against Blue
stain protein ladder molecular weight in the lane 1. The SDS-PAGE gel shows the flow through
lane in which the initial flow through was saved after passing the filtered lysate through the
nickel resin beads in lane 2. The remaining lanes show the elution of the bound proteins with
dilutions of imidazole. The lane 3 represents elution of the bound protein with Ultra-Pure
distilled water + 10 mM imidazole. The lane 4 represented elution sample with dilution of 100
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mM imidazole, and the lane 5 represented the sample with dilution of 500 mM imidazole. The
protein size of CptA was indicated at ~240 kDa (235 kDa).
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Figure 4: Purification of CptA CTerm (98 kDa) and full-length CptA (235 kDa).

Figure 4: Purification of CptA CTerm (98 kDa) and full-length CptA (235 kDa). Purification of
6X-His tagged recombinant CptA expressed in BL21(DE3) pLysS + pRIL strain of E. coli cells
containing pET32a using a nickel resin column. The samples loaded were compared against
BLUEstain protein ladder molecular weight in the first lane. SDS-PAGE analysis of proteins
eluted from the nickel beads with 125mM, 250 mM, 500mM or 1M imidazole for the both the Nterm and the C-term. The protein size of full-length CptA was indicated at ~240 kDa (235 kDa)
and the CptA’s C-term domain was indicated at 98 kDa selected in red boxes.
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Figure 5: Repeated Purification of CptA CTerm (98 kDa) and NTerm (163 kDa).

Figure 5: Repeated Purification of CptA C-term (98 kDa) and N-term (163 kDa). SDS-PAGE
analysis of proteins eluted from the nickel beads with 10mM, 100 mM, or 250 mM imidazole.
Approximate molecular weights are indicated from BLUEstain protein ladder compared to
samples loaded.

250
mM

27

MW
kDa

Hela N N+ C

C+

-240

-165
-125
-93
-72

-57
-42
-31
-24

-18
-15

-a

Figure 6: Adherence of CptA N-Term and C-Term peptides to HeLa cells.

Figure 6: Adherence of CptA N-Term and C-Term peptides to HeLa cells. Purified peptides were
either added to HeLa monolayers for 15 minutes or developed as the peptide alone. The adherent
proteins were developed by western blot. Approximate molecular weights indicated. Lane 1:
HeLa cells alone; Lane 2: N-term peptides alone; Lane 3: N-term peptides added to HeLa cells;
Lane 4: C-term peptides alone; Lane 5: C-term peptides added to HeLa cells.
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Figure 7: Both CptA N-Term and C-Term bind to HeLa cells

Figure 7: Both CptA N-Term and C-Term bind to HeLa cells. Purified peptides were added to
HeLa monolayers or empty wells (bare polystyrene). Non-adherent protein was washed away,
and adherent protein was detected by Western blot. Lane 1: HeLa cells alone; Lane 2: N-term
peptides alone; Lane 3: N-term peptides added to HeLa cells; Lane 4: N-term peptides added to
bare polystyrene wells; Lane 5: C-term peptides alone; Lane 6: C-term peptides added to HeLa
cells; Lane 7: C-term peptides added to bare polystyrene wells.
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Figure 8: Full Length CptA hemolytic activity on human red blood cells.

Figure 8: Full Length CptA hemolytic activity on human red blood cells. A hemolytic assay was
performed by incubating full length CptA saved from the purification steps with human
erythrocyte cells washed in PBS and incubated for 2 hours at 37ºC. The liberated hemoglobin
was measured by optical density at 405nm.
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Figure 9: Cytotoxic assay using N-terminal and C-terminal domain of CptA

Figure 9: Cytotoxic assay using N-terminal and C-terminal domain of CptA. The HeLa
monolayers were washed with PBS and incubated with the purified peptides in a 5% CO2
incubator at 37C for 2 hours. The cells were assessed using trypan blue exclusion and viewed
under an inverted microscopy. Fig. 9A shows N-term/ CptA added to HeLa cells and Fig. 9B
shows C-term added to HeLa cells. N-terminal domain has an affinity for plasma membrane.
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Figure 10: CptA’s C-term blocked cytotoxic activity of full-length CptA in HeLa Cells.

Figure 10: CptA’s C-term blocked cytotoxic activity of full-length CptA in HeLa Cells. HeLa
cells were washed with PBS and incubated with the purified peptides in a 5% CO2 incubator at
37C for 2 hours. The cells were stained with trypan blue exclusion and viewed under an
inverted microscopy. C-term peptide prevented full-length toxin-mediated cytotoxicity.
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Figure 11: Homology model of full length CptA toxin modeled after c3fy3A_.

Figure 11: Homology model of full length CptA toxin modeled after highest score template
c3fy3A_ using Phyre2.0 prediction protein modeling software. The template c3fy3A_ was a
truncated protein from P. mirabilis.
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Discussion
In the current study, we had the initial focus to characterize the CptA of S. amnii. The
first research focus was to express the full-length CptA and the domains of CptA (N-term and Cterm) in pET32a expression vectors in E. coli cells. It was hypothesized that E. coli cells could
express the full-length peptides and domain peptides. This hypothesis was confirmed, as the
SDS-PAGE gel analysis showed that the recombinant proteins were successfully expressed in
BL21(DE3) pLysS + pRIL E. coli cells and purified by nickel ion column. In this experiment, we
faced obstacles that included smearing of the proteins in the lane as well as the appearance of the
other bands that were not the recorded protein size. While we were not able to determine the
reason that the other bands showed up, we assumed that this may be due to the breakdown of the
protein.
In the second objective, the focus of the study was to determine which domain of CptA is
responsible for the cytotoxic and hemolytic activity. The data of this study contributes a clearer
understanding of the roles of the CptA. We confirmed our hypothesis that CptA is hemolytic and
that the N-terminal domain that codes for CptA was also hemolytic as it had an affinity for
plasma membrane allowing the protein to perforate epithelial cell monolayers. While previous
research (Gentile et al. 2020) has focused on CptA, these results of this experiment demonstrate
that even the separable domains of CptA retain their function. Our work has revealed that the Cterminal domain is involved in binding to the host cell surface and that the N-terminal domain is
the pore-forming domain. The results indicate that the C-terminal domain peptides was not
cytotoxic and has a role in binding to some specific host cell receptor on epithelial cells.
Additionally, our findings supported the theory of full-length having hemolytic and
cytotoxic effects on epithelial cells through in-silico analysis. Based on in-silico analysis of full
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length CptA, it was reported that CptA was homologous with a small portion of a truncated
hemolysin found in P. mirabilis. The in-silico analysis also matched a region of the secretion
domain, Filamentous hemagglutinin (FhaB), in Bordetella species. Thus, the similar structural
homology present supports in our Phyre 2.0 supports past studies that note that CptA toxin is
secreted through a Type Vb two-partner secretion system where the effector, CptA which is
homologous to Fha in Bordetella pertussis, is secreted by a transporter similar to FhaC in
Bordetella pertussis.
In the third objective of this study, the focus was to characterize the role C-term plays in
cytotoxicity. It was determined that C-term can prevent full-length CptA mediated cytotoxicity
through competitive binding kinetics with some host cell surface receptors. Currently, it is not
known what the host cell receptor in the protein-host binding interactions is. Therefore, further
studies can be done to determine the specific host receptor as well as determine cytotoxicity over
a longer period. Additionally, different epithelial cells can be used as model cell lines in the
research. In future studies, C-term can be added first and incubated for a longer period to achieve
saturation before CptA is added.
Other future works to advance the studies also include using CptA proximal binding
partners on the target cells to determine structural protein composition via mass spectrometry to
further understand how the toxin works and its function. Second, we can adapt methodology to
determine the best way to purify the product with less breakdown protein. Lastly, further
research can be done to design therapies to treat and prevent the prevalence of Sneathia species,
which is common in the vaginal microbiome and prevalent in women of African ancestry.
Sneathia amnii has been implicated in gynecologic and obstetric complications associated
with the vaginal microbiome. Sneathia amnii is categorized as a pathogenic anaerobe that
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ascends the uterine cavity into sterile environments of the cervix and traverses epithelial cells to
cross into amniotic fluid where it can be detected (Jefferson 2012). Although the specific role of
Sneathia amnii is still being explored, our study has started to characterize the components of
CptA and its role in idiopathic conditions like PTB and BV. Sneathia amnii is implicated in
intrauterine infections and inflammations which are linked to preterm birth and prevalent in
women of African ancestry (Jefferson 2012; Fettweis et al. 2014). Because women of African
descent are more likely to develop BV, which is a gateway to more adverse outcomes including
pregnancy complications. Studying S. amnii, its cytotoxin, and the role the bacteria plays in
preterm-birth complication is essential in mitigating derived idiopathic conditions as well as
reducing the overall rate of PTB as well as the health costs attributed to preterm birth deliveries.
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